Stock Ranking
Healthcare Stock Ranking · October 2026
Published 04 Oct 2026
•
Updated 04 Oct 2026
This sector ranking is based on quantitative metrics grouped into four factors:
Value : measures how expensive a stock is relative to the company’s fundamentalsGrowth : measures how quickly the business is expandingQuality : assesses business durability, with a focus on debt levels, margins, and return on invested capitalMomentum : analyzes the current direction and strength of the stock price trendCompanies with strong fundamentals have historically delivered superior long-term performance. However, quantitative metrics alone are not sufficient to evaluate a business. Understanding how a company operates, along with its catalysts and risks, provides a more complete picture.
Quantitative rankings should be used as a starting point for research rather than as standalone investment decisions.
The ranking includes companies across different market capitalizations. Smaller-cap stocks may offer stronger growth opportunities but generally carry higher volatility and business risk.
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Penumbra Inc
+23%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Bottom 40%
Sector Ranking
Catalysts
Stroke thrombectomy, international
expansion
Risks
Product concentration, premium
valuation
Sector: Healthcare
ClarityVesting.com
Penumbra develops medical devices for stroke and vascular clot removal, a market supported by durable healthcare demand. Revenue growth, margin improvement, rising cash flow, and a very clean balance sheet make its operating profile particularly noteworthy.
Stock analysis Penumbra Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
DaVita HealthCare Partners Inc
+55%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Home dialysis, value-based kidney
care
Risks
Medicare rates, high debt, labor
costs
Sector: Healthcare
ClarityVesting.com
DaVita is a specialized kidney care provider with recurring demand, national scale, strong cash generation, and solid profitability. Its focused dialysis franchise and expanding care models support a compelling long-term healthcare business profile.
Stock analysis DaVita HealthCare Partners Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
BeiGene Ltd
+3%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 60%
Sector Ranking
Catalysts
BRUKINSA share gains, pipeline
approvals
Risks
BRUKINSA concentration, BTK
competition
Sector: Healthcare
ClarityVesting.com
BeiGene has become a large commercial oncology company built around BRUKINSA, with fast revenue growth, improving margins, and positive free cash flow. Its move from heavy losses to profitability makes its long-term profile far more substantial than that of a typical biotech.
Stock analysis BeiGene Ltd
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Encompass Health Corp
+118%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Bed expansion, aging population,
FCF growth
Risks
Medicare rates, staffing costs,
leverage
Sector: Healthcare
ClarityVesting.com
Encompass Health is a specialized rehabilitation hospital operator with national scale, steady revenue growth, rising cash generation, and margins well above much of healthcare. That focused post-acute care position gives the business a distinctive profile.
Stock analysis Encompass Health Corp
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
Ansell Ltd
+42%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 80%
Sector Ranking
Catalysts
Kimberly-Clark PPE integration,
Margin rebound
Risks
Glove price swings, Integration
execution
Sector: Healthcare
ClarityVesting.com
Ansell makes protective gloves and safety products for hospitals and industrial users worldwide. Revenue, margins, and cash flow have improved sharply, while its shift toward more specialized protection markets gives the business a stronger profile than a pure commodity glove supplier.
Stock analysis Ansell Ltd
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Exelixis Inc
+179%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 80%
Sector Ranking
Catalysts
Cabozantinib expansion, pipeline
progress
Risks
Cabozantinib reliance, trial
failures
Sector: Healthcare
ClarityVesting.com
Exelixis is a profitable oncology biotech built around CABOMETYX, with strong cash flow, high margins, and low debt. What stands out is its unusual mix of commercial scale and biotech growth potential as it works to broaden its cancer pipeline.
Stock analysis Exelixis Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Veeva Systems Inc
-2%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Vault growth, Data Cloud expansion
Risks
Premium valuation, big-client
spending
Sector: Healthcare
ClarityVesting.com
Veeva Systems provides cloud software for life sciences, covering commercial, clinical, regulatory, quality, and data workflows. Strong recurring revenue, rising cash flow, high margins, and a near-debt-free balance sheet give it an especially compelling long-term business profile.
Stock analysis Veeva Systems Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Halozyme Therapeutics Inc
+176%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 90%
Sector Ranking
Catalysts
New ENHANZE launches, Royalty
growth, FCF rise
Risks
Partner concentration, High
leverage metrics
Sector: Healthcare
ClarityVesting.com
Halozyme Therapeutics generates royalties and licensing income from its ENHANZE drug-delivery platform, a model that has produced unusual profitability and cash flow for biotech. Its strength comes from scalable partner-driven growth backed by commercialized products.
Stock analysis Halozyme Therapeutics Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Pro Medicus Limited
+208%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 40%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 60%
Sector Ranking
Catalysts
U.S. contract wins, cloud imaging
demand
Risks
Rich valuation, contract timing,
U.S. focus
Sector: Healthcare
ClarityVesting.com
Pro Medicus supplies high-performance medical imaging software used by major health systems. Rapid growth, exceptional margins, strong cash generation, and a debt-light balance sheet make it a standout name, with the key debate centered on valuation.
Stock analysis Pro Medicus Limited
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
Hinge Health Inc
+160%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 90%
Sector Ranking
Catalysts
Employer wins, payer expansion, FCF
scale
Risks
Competition, margin volatility,
long sales
Sector: Healthcare
ClarityVesting.com
Hinge Health delivers digital musculoskeletal care for employers and health plans, blending software with clinical support. Rapid revenue growth, rising free cash flow, and a very low-debt balance sheet stand out in its operating progress.
Stock analysis Hinge Health Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Cardinal Health Inc
+414%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Specialty expansion, FCF strength
Risks
Thin margins, peer pricing pressure
Sector: Healthcare
ClarityVesting.com
Cardinal Health is a healthcare distribution giant moving medicines and medical supplies at massive scale. Earnings and cash flow have improved sharply, while specialty services bring a stronger growth dimension to the story.
Stock analysis Cardinal Health Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
United Therapeutics Corporation
+187%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 50%
Sector Ranking
Catalysts
Tyvaso DPI growth, transplant
pipeline
Risks
Tyvaso concentration, patent
pressure
Sector: Healthcare
ClarityVesting.com
United Therapeutics is a rare-disease biotech built around a highly profitable pulmonary hypertension franchise. Strong cash flow, minimal leverage, and growing transplant-related ambitions add to its long-term interest.
Stock analysis United Therapeutics Corporation
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
Ligand Pharmaceuticals Incorporated
+277%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 70%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 90%
Sector Ranking
Catalysts
Royalty pipeline, Captisol, new
deals
Risks
Partner dependence, lumpy revenue,
debt
Sector: Healthcare
ClarityVesting.com
Ligand Pharmaceuticals generates royalties, licensing income, and Captisol-related revenue from a broad portfolio of partnered drug assets. Recent growth, strong margins, and improving cash flow highlight the appeal of its royalty-platform model.
Stock analysis Ligand Pharmaceuticals Incorporated
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Incyte Corporation
+76%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Opzelura growth, pipeline readouts,
M&A
Risks
Jakafi concentration, trial
setbacks, rivals
Sector: Healthcare
ClarityVesting.com
Incyte is a profitable biotech company built on a leading hematology franchise and a growing mix of newer medicines. Strong cash flow, very low debt, and faster-than-sector growth make it a notable example of long-term business quality.
Stock analysis Incyte Corporation
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
Krystal Biotech Inc
+502%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Bottom 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 80%
Sector Ranking
Catalysts
Vyjuvek growth, pipeline expansion
Risks
Single-product reliance, trial
setbacks
Sector: Healthcare
ClarityVesting.com
Krystal Biotech has evolved into a profitable gene-therapy company led by Vyjuvek, with fast revenue growth, strong margins, positive cash generation, and very low debt. The key question is whether that rare-disease foothold can expand into a broader platform.
Stock analysis Krystal Biotech Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=122.304;CanvasH=192;configurationEnd;
Large cap
Medpace Holdings Inc
+210%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 50%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 90%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 70%
Sector Ranking
Catalysts
Biotech outsourcing, backlog
growth, buybacks
Risks
Biotech funding cycle, trial
cancellations
Sector: Healthcare
ClarityVesting.com
Medpace manages clinical trials for drug and biotech companies through a focused full-service model. High margins, rising cash flow, and deep therapeutic expertise set it apart within healthcare services.
Stock analysis Medpace Holdings Inc
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=180.864;CanvasH=192;configurationEnd;
Mid cap
National HealthCare Corporation
+272%
5y price change
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=240;CanvasH=192;configurationEnd;
Value
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=193.728;CanvasH=192;configurationEnd;
Growth
Top 80%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=160.128;CanvasH=192;configurationEnd;
Quality
Top 60%
CopyRight:SVG Design Editor;
configurationStart;Unit=smInches;Dpi=96;Division=4;Grid=True;Zoom=5;CanvasW=192.672;CanvasH=192;configurationEnd;
Momentum
Top 80%
Sector Ranking
Catalysts
Margin recovery, occupancy,
homecare mix
Risks
Medicare rates, staffing costs,
regulation
Sector: Healthcare
ClarityVesting.com
National HealthCare Corporation runs skilled nursing, senior living, and homecare services with a notably strong balance sheet, recovering margins, and rising cash generation. Its appeal lies in resilient care demand paired with unusually disciplined finances.
Stock analysis National HealthCare Corporation
This article is for informational purposes only and does not constitute financial advice. Some content is AI-generated. See Disclaimer
